复方丹参注射液联合奥扎格雷治疗糖尿病足疗效观察

目的：探讨复方丹参注射液联合奥扎格雷治疗糖尿病足的临床疗效。方法：将84例确诊为糖尿病足的患者随机分为奥扎格雷常规治疗组（常规组）和复方丹参注射液联合奥扎格雷治疗组（联合组）,结合肌电图、血液流变学和各项生化指标检测评价疗效。结果：两组患者治疗后,上述指标均有不同程度改善,联合组运动神经传导速度、感觉神经传导速度显著加快（P〈0.01）;血液黏度明显下降（P〈0.01）;各项生化指标明显改善（P〈0.01）。结论：复方丹参注射液联合奥扎格雷治疗糖尿病足,有助于糖尿病足获取更好的疗效。     

奥扎格雷钠联合疏血通治疗急性脑梗死疗效观察

目的:研究奥扎格雷钠联合疏血通治疗急性脑梗死的临床疗效.方法:将2006年1月至2008年12月发病时间在6～72 h以内的急性脑梗死患者100例随机分成A、B两组各50例,分别接受奥扎格雷钠联合疏血通治疗及复方丹参联合银杏叶治疗10～14 d,并适当脱水、降压等对症治疗.对两组治疗前及治疗后90d的神经功能缺损程度评分(NIHSS)、日常生活能力评分(ADL)及不良反应进行比较.结果:治疗后90 d时,A组NIHSS评分、ADL评分均明显优于B组,P均<0.05;两组均无明显不良反应.结论:奥扎格雷钠联合疏血通治疗急性脑梗死可明显改善神经功能,提高日常生活能力.     

苦碟子联合奥扎格雷钠治疗脑梗死疗效观察

目的探讨苦碟子联合奥扎格雷钠治疗脑梗死的临床疗效。方法选择2007年6月至2011年1月收治脑梗死患者120例,随机分为治疗组60例和对照组60例,两组均给予苦碟子注射液30 ml加生理盐水250 ml中静脉滴注,每天1次,治疗组再此基础上加用奥扎格雷钠氯化钠注射液100 ml（含奥扎格雷钠80 mg）静脉滴注,每天2次,疗程均为14 d。结果治疗组治愈15例,显著好转26例,好转16例,总有效率为95%;对照组组治愈12例,显著好转22例,好转11例,总有效率为75%,两组比较差异有统计学意义（P〈0.05）。结论苦碟子联合奥扎格雷钠治疗脑梗死能显著改善患者神经功能缺损程度,提高患者生存质量。     

奥扎格雷钠联合血塞通治疗脑梗死85例疗效观察

目的:观察注射用奥扎格雷钠联合血塞通治疗脑梗死的治疗效果.方法:观察2006年10月-2007年10月脑梗死85例,随机分治疗组(43例)和对照组(42例),治疗组以奥扎格雷钠联合血塞通治疗,对照组应用长春西汀合丹参注射液治疗.2组均连用14d为1个疗程.结果:治疗组奥扎格雷钠联用血塞通治疗脑梗死,有效率达90.7%,明显优于对照组.结论:奥扎格雷钠联合血塞通能有效治疗脑梗死,值得在临床中推广.     

奥扎格雷钠治疗进展性脑梗死32例疗效观察

1　资料与方法1.1　病例资料　随机将64例患者分为治疗组与对照组。治疗组3 2例,男2 1例,女11例;年龄46～79岁,平均64 2岁,病情进展的平均时间为19 1h。对照组3 2例,男2 0例,女2 1例;年龄44～78岁,平均62 3岁,病情进展的平均时间为18 4h。两组间的发病时间、年龄、病程及神经功能评分无显著差异(P >0 0 5 )。1.2　入选标准　①从我科住院患者中选取发病72h内就诊,发病6h后局部神经功能缺损症状进行性加重的进展性脑梗死患者;②经头颅CT或MRI证实,并排除脑出血;③脑梗死为首次发病或既往有脑梗死史已治愈,未留明显后遗症。1.3　治疗方…     

奥扎格雷钠治疗急性脑梗死36例疗效观察

目的探讨奥扎格雷钠治疗急性脑梗死的临床疗效。方法急性脑梗死患者72例,随机分成治疗组和对照组,两组患者均给予控制血压、调脂、改善脑水肿、改善脑血循环及脑细胞代谢活化剂治疗,治疗组用5%葡萄糖注射液250 ml＋奥扎格雷钠80 mg,静脉滴注,1日2次,疗程21 d;对照组用5%葡萄糖注射液250 ml＋维脑路通注射液600 mg,静脉滴注,每日1次,疗程21 d。两组中有糖尿病者改用生理盐水稀释。治疗前后两组病例分别进行神经功能缺损程度评分。结果治疗组有效率86.1%,优于对照组58.3%（P〈0.01）,未发现明显不良反应。结论奥扎格雷钠治疗急性脑梗死安全有效。     

联合应用奥扎格雷钠和红花注射液治疗急性脑梗塞的疗效观察

以2012年9月~2014年3月我院156例脑梗塞患者为研究对象,将其随机分为两组,对照组78例联合血栓通、低分子右旋糖酐治疗;观察组78例联合奥扎格雷钠、红花注射液治疗,观察比较两组的临床治疗效果。结果观察组治疗总有效率97.44%,对照组总有效率76.92%,两组比较差异具有统计学意义(P0.05);两组的神经功能缺损评分均明显低于治疗前,观察组的改善效果明显好于对照组(P0.05)。联合应用奥扎格雷钠和红花注射液治疗脑梗塞的疗效明显,值得临床推广应用。     

银杏叶与奥扎格雷钠联合治疗急性脑梗塞疗效观察

我们从2004年6月至2005年6月应用银杏叶联合奥扎格雷钠治疗80例急性脑梗塞(CI)患者取得了较好的疗效,同时观察了两药联合对CI患者血粘度和血小板聚集功能的影响,现报告如下。1对象和方法1)研究对象及分组:根据病史、神经系统检查和脑CT扫描确诊为急性CI患者(发病6~72 h内)80例,随机分为银杏叶注射液和奥扎格雷钠联合治疗组40例和复方丹参对照组40例,两组患者在性别、年龄、神经功能缺损评分方面无统计学差异。2)治疗方法:①治疗组:入院后立即给予银杏叶注射液(万荣三九药业有限公司生产,批号:0310261)20 mL加入生理盐水250 mL静脉滴注,1…     

奥扎格雷钠治疗急性脑梗塞的疗效观察

目的观察奥扎格雷钠治疗急性脑梗塞的疗效。方法选择2005年1月至2007年2月本院住院经CT或MRI确诊的急性脑梗塞患者70例,发病均在3d内。将患者随机分为治疗组和对照组,各35例。对照组常规用药,给予丹参,阿司匹林治疗,治疗组加用奥扎格雷钠注射剂80mg静脉滴注,2次／d,疗程14d。结果治疗前后两组神经功能缺失评分减少程度比较有显著性差异（P〈0．01）,两组总有效率分别为93％、78％（P〈0．05）。结论奥扎格雷钠治疗急性脑梗塞有较好的疗效及安全性。     

奥扎格雷钠治疗急性脑梗死疗效观察

目的观察早期应用奥扎格雷钠注射液治疗急性脑梗死的疗效。方法将我院2004年4月至2007年4月所收治的120例急性脑梗死病人随机分为两组,各60例。治疗组用奥扎格雷钠注射液80 mg静点,每日2次。对照组用川芎嗪注射液120 mg静点,每日1次。14 d为一疗程,均两个疗程。两个疗程后观察两组神经功能缺损情况。治疗前两组年龄、性别、病情程度无显著差异(P<0.05)。结果治疗组疗效明显优于对照组(P<0.01)。结论早期应用奥扎格雷钠注射液治疗急性脑梗死疗效可靠、安全。     

糖尿病足部溃疡综合护理干预效果观察

糖尿病足部溃疡(diabetic foot ulcer,DFU)是糖尿病慢性、全身性、代谢性疾病的局部恶化性表现,其发病和进展与糖尿病的周围血管病变、周围神经病变以及(原发、继发)感染三大因素的协同作用密切相关。小面积DFU的早期局部处理不妥往往     

Infected diabetic foot ulcers

Infections of diabetic foot ulcers are a common, longstanding complication of poorly controlled diabetes. They result from the interplay of peripheral neuropathy and peripheral vascular disease. In most cases, diabetic foot infections are polymicrobial, and deep tissue culture after debridement is essential for identifying the true pathogens. Treatment includes bed rest, empiric and specific antibiotic therapy, and good control of diabetes.     

Managing diabetic foot ulcers

This article discusses optimal care for a diabetic foot wound including use of a protocol with standards for assessment, treatment, and prevention. Patient and family education is also pivotal to the plan's success.     

Sustained silver-releasing dressing in the treatment of diabetic foot ulcers

This study investigated the clinical performance and safety of a sustained silver-releasing foam dressing, Contreet Foam, in the treatment of diabetic foot ulcers. Twenty-seven patients with diabetic foot ulcers of grade I or II (Wagner's classification) were followed for six weeks: one week run-in using Biatain dressings, four weeks' treatment with Contreet dressings. Four ulcers healed during the four-week treatment with Contreet 56% in average. Contreet Foam showed good exudate management properties and was considered easy to use. Only two infections occurred showed that all six of the non-study ulcers developed an infection during the study. All ulcers (study ulcers as well as non-study ulcers) were treated according to good practice of diabetic wound care. There were no directions for the treatment of secondary wounds. No device-related adverse events were observed. This study demonstrated that Contreet Foam is safe and easy to use and effectively supports healing and good wound progress of diabetic foot ulcers.     

Novel biological therapies for the treatment of diabetic foot ulcers

Introduction: The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2% of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculation. The increase in the prevalence of DFU has prompted researchers to find new therapies for the management of DFU.

Areas covered: This review presents the current status of novel biological therapies used in the treatment of DFU. Literature information and data analysis were collected from PubMed, the website of the American Diabetes Association, and ClinicalTrials.gov. The keywords used in the search were: DM, DFU, complications of DM.

Expert opinion: Many biological agents have been investigated in a bid to find an effective therapy for DFU. These include growth factors (platelet-derived growth factor, vascular endothelial growth factor etc), stem cells (epithelial progenitor-, adipose-derived stem cells etc), anti-diabetic drugs (insulin, exendin-4), herbs, urokinase, dalteparin, statins and bio-agents such as acid peptide matrix. Biological agents that can reduce hyperglycaemia, increase sensation, microcirculation and oxygenation and repair lost tissue are the most ideal for the treatment of DFU.     

高锰酸钾联合德莫林换药用于糖尿病足的疗效观察及护理

目的:探讨高锰酸钾联合德莫林治疗糖尿病足的临床效果。方法:按糖尿病足Wagner分级法评估20例患者病变的临床症状、程度,有针对性的进行治疗和护理干预,避免糖尿病足的发生、发展。结果:通过对20例不同分期的糖尿病足患者进行高锰酸钾溶液浸泡联合德莫林换药治疗,在血糖控制良好条件下,取得了理想效果,有效率95%。结论:使用高锰酸钾溶液浸泡联合德莫林用于糖尿病足换药治疗是安全、有效的,值得临床推广应用。     

湿性愈合疗法联合高压氧治疗糖尿病足溃疡的效果

目的 探讨湿性愈合疗法联合高压氧治疗糖尿病足溃疡的应用.方法 通过在临床实践中以传统换药为基础,再使用湿性愈合疗法联合高压氧治疗糖尿病足溃疡,评价患者对该疗法的满意度、切口愈合率、愈合时间、换药次数,并与单独使用传统换药相比较,进行两者之间的差异分析.结果 实验组显效18例（85.7％）,有效3例（14.3％）,对照组显效10例（47.6％）,有效6例（28.6％）,无效5例（23.8％）,两组比较差异有统计学意义（x2=5.68,P＜0.05）;愈合时间实验组需要（27.8±3.75）d,对照组需要（38.6±3.81）d,两组比较差异有统计学意义（t=9.2,P＜0.05）;换药次数实验组需要（15.6±3.45）次,对照组需要（24.8±3.62）次,两组比较差异有统计学意义（t=8.4,P＜0.05）;患者满意度实验组为95.4％优于对照组的68.9％,两组比较差异有统计学意义（t=5.15,P＜0.05）.结论 采用以传统换药为基础,再使用湿性愈合疗法联合高压氧治疗糖尿病足溃疡能明显提高创面愈合率,减少换药次数,减轻护士工作量,其结果可为合理应用该疗法促进糖尿病足溃疡愈合又可减少患者的痛苦提供临床依据.     

Surrogate end points for the treatment of diabetic neuropathic foot ulcers

OBJECTIVE: The goal of this study was to determine whether surrogate markers based primarily on changes in the size of a wound can be used to correctly predict which individuals with diabetic neuropathic foot ulcers will heal after 12 or 20 weeks of care. RESEARCH DESIGN AND METHODS: This is a retrospective cohort study using the Curative Health Services database. As many as 39,918 neuropathic wounds on 20,213 individuals with diabetes were evaluated. Seven surrogates based on changes in wound size were evaluated. RESULTS: Surrogates measured after 2, 4, or 8 weeks of care and based on percentage change in area, log healing rate, and log area ratio discriminated well with respect to differentiating between those wounds that healed and those that did not heal by the 12th or 20th week of care. For example, after 4 weeks of care, the percentage change in area can be used to correctly discriminate 76% of the time between those that healed and those that did not by the 20th week of care. CONCLUSIONS: The surrogate markers can be used in clinical trials such that shorter and smaller trials can be conducted with reasonable accuracy in order to determine which potential new therapeutics should be studied in larger, longer trials. In addition, the surrogates may also benefit clinicians when they are trying to decide whether a wound care therapy will ultimately be successful.     

糖尿病足创面处理研究进展

本文系统阐述了糖尿病足创面修复的机制和意义、时机把握、治疗原则、方法选择原则和技巧。特别强调要以糖尿病足清创和感染处理为基础,阐述了创面修复的方式和方法。针对不同阶段的创面,对遵循相应处理原则做出诠释。列举了近年来一些在创面的不同治疗阶段促愈合所应用的新技术、新方法。同时将糖尿病足创面修复的根本目标是功能康复的观念贯穿文章始终。为临床糖尿病足创面的预防及修复提供有效的治疗方案,进行了经验总结。